The conference features faculty consisting of clinicians and researchers from across the USA & other countries.

Paige Armstrong, MD, MHSLCDR, CDC; Rickettsial Diseases: Epidemiologic Trends, Clinical Diagnosis and Management

Adrian Baranchuk, MD, FACC, FRCP, FCCS, Queen's University; Systematic Approach for the Diagnosis and Treatment of Lyme Carditis

Choukri Ben Mamoun, PhD, Yale University; Continuous In Vitro Culture of Babesia duncani in Human Red Blood Cells: An Inflection Point in Diagnosis and Therapy of Human Babesiosis

George Chaconas, PhD, University of Calgary; An Inside Look at the Life of a Pathogen: Intravital Imaging to Study Hematogenous Dissemination of the Lyme Disease Spirochete

Charles Chiu, MD, PhD, University of California (San Francisco); Multi-Omics Approaches to Diagnosis of Lyme Disease and Other Tick-Borne Infections

Madeleine W. Cunningham, PhD, University of Oklahoma; From Bench to Bedside: Anti-Neuronal Autoantibodies in Lyme Disease and Beyond

J. Stephen Dumler, MD, Uniformed Services University; Human Granulocytic Anaplasmosis-Emerging Faster than Lyme Disease

Ingeborg Dziedzic, MD, ABAARM, Pleasant Vision Ophthalmology Practice; Potential Late Ophthalmic Consequences of Lyme Disease

Brian Fallon, MD, MPH (Conference Director), Columbia University; Clinical Trials: Biologic & Clinical Measures of Change

Holly M. Frost, MD, University of Colorado; The Pitfalls of Serologic Assays for the Diagnosis of Tick-Borne Diseases: A Case Series and Review of the Literature

Osama Haddad, MD, Mayo Clinic; Mitral Valve Endocarditis: A Rare Manifestation of Lyme Disease

Emir Hodzic, DVM, MSC, PhD University of California (Davis); Post-Treatment Persistence of Antimicrobial Tolerant Replicatively-Auttenated Borrelia burgdorferi in a Mouse Model

Lance A. Liotta, MD PhD, George Mason Univ; Shedding of Urinary Tick Pathogen-Specific Proteins in Patients with Tick-Borne Diseases

Joanna Lyon, PharmD, MEd, MHS, CHES, BCGP, University of Maryland; The Possible Association Between the Human ABCB1 Gene and Post-Treatment Lyme Disease Syndrome

Margaret R. MacDonald, MD, PhD, The Rockefeller University; Atypical Features of Lyme Disease in North America in Human Red Blood Cells: An Inflection Point in Diagnosis of Human Babesiosis

Robert K. Naviaux, MD, PhD, Univ. of California (San Diego); Post-Treatment Persistence of Antimicrobial Tolerant Replicatively-Auttenated Borrelia burgdorferi in a Mouse Model

Peter Novak, MD, PhD, Harvard University; Neurologic, and Cardiac Effects of Lyme Disease

Mark J. Soloski, PhD, Johns Hopkins University; Host Immune Response in Lyme Borreliosis

Robert K. Naviaux, MD, PhD, Univ. of California (San Diego); Mitobolomic Features of Acute and Chronic Lyme Disease-Early Results from the UCSD Lyme-ME/CFS Comparison Study

Robert K. Naviaux, MD, PhD, Univ. of California (San Diego); Late Ophthalmic Consequences of Lyme Disease

Peter Novak, MD, PhD, Harvard University; Neurologic Correlates of Post-Treatment Lyme Disease Syndrome

Mark J. Soloski, PhD, Johns Hopkins University; Host Immune Response in Lyme Borreliosis

Daniel E. Sonenshine, PhD, Old Dominion University; powassian virus, and anaplasmosis; late ophthalmic consequences of Lyme; clinical trials; pitfalls of serologic diagnosis; mitral valve endocarditis; Post-Treatment persistence; shedding of urinary tick pathogen-specific proteins; Post-Treatment Lyme Disease Syndrome-human ABCB1 gene, & neurological correlates; powassan; metabolomic features of acute & chronic Lyme; host immune response in Borreliosis; climate change & spread of tick-borne disease in North America; Obsessive-compulsive disorder; Gut-Brain-Axis.

Learning Objectives:
Clinicians should have better ability to use current diagnostic tests and to understand the difference between direct & indirect testing; Clinicians should be able to describe the manifestations and tests for Babesia duncani, spotted fevers, Powassan virus, and Anaplasma; Clinicians should be able to explain to patients that changes in the microbiome may impact brain function; Clinicians should be able to describe some of the key immune biomarker findings in Lyme disease; and Clinicians should be able to describe the possible ocular, neurologic, and cardiac effects of Lyme disease.

This activity has been approved for AMA PRA Category 1 Credit™

This activity is supported by independent educational grants from: Steven & Alexandra Cohen Foundation & Igenex Labs, Inc.

www.LymeDiseaseAssociation.org